VYGR Logo

Voyager Therapeutics, Inc. (VYGR) 

NASDAQ
Market Cap
$398.59M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
768 of 776
Rank in Industry
428 of 433

Largest Insider Buys in Sector

VYGR Stock Price History Chart

VYGR Stock Performance

About Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear …

Insider Activity of Voyager Therapeutics, Inc.

Over the last 12 months, insiders at Voyager Therapeutics, Inc. have bought $0 and sold $379,660 worth of Voyager Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Voyager Therapeutics, Inc. have bought $20.58M and sold $3.83M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 4,395,588 shares for transaction amount of $39.03M was made by NEUROCRINE BIOSCIENCES INC (10 percent owner) on 2023‑02‑23.

List of Insider Buy and Sell Transactions, Voyager Therapeutics, Inc.

2024-10-02SaleChief Legal Officer
5,999
0.0109%
$5.82$34,914+20.62%
2024-04-02SalePresident and CEO
12,115
0.0222%
$9.86$119,454-21.09%
2024-04-02SaleChief Operating Officer
1,357
0.0025%
$9.88$13,407-21.09%
2024-02-21SalePresident and CEO
13,033
0.0278%
$7.46$97,226+7.20%
2024-02-21SaleChief Financial Officer
3,764
0.008%
$7.46$28,079+7.20%
2024-02-21SaleChief Operating Officer
3,966
0.0084%
$7.45$29,547+7.20%
2024-02-21SaleChief Scientific Officer
3,365
0.0072%
$7.47$25,137+7.20%
2024-02-20SaleChief Scientific Officer
602
0.0013%
$7.68$4,623+8.12%
2024-01-17SaleChief Operating Officer
2,543
0.0054%
$7.15$18,182+8.95%
2024-01-17SaleChief Scientific Officer
1,266
0.0027%
$7.18$9,090+8.95%
2023-10-03SaleChief Financial Officer
13,567
0.0298%
$6.99$94,833+9.57%
2023-09-15SaleChief Scientific Officer
10,500
0.0245%
$8.16$85,680-2.64%
2023-07-06SaleChief Scientific Officer
5,500
0.0137%
$10.80$59,400-22.70%
2023-06-30SaleChief Scientific Officer
5,000
0.0123%
$11.41$57,050-28.03%
2023-04-03SalePresident and CEO
7,437
0.0187%
$7.83$58,232+2.19%
2023-04-03SaleChief Operating Officer
1,259
0.0032%
$7.83$9,858+2.19%
2023-03-15SaleChief Operating Officer
15,373
0.041%
$8.20$126,059+0.25%
2023-02-23Purchase10 percent owner
4.4M
14.7056%
$8.88$39.03M+14.60%
2023-02-17SaleSenior VP & General Counsel
3,297
0.0086%
$7.45$24,563+6.59%
2023-02-17SaleChief Scientific Officer
738
0.0019%
$7.45$5,498+6.59%

Insider Historical Profitability

<0.0001%
NEUROCRINE BIOSCIENCES INC10 percent owner
8575316
15.7249%
$7.3120+7.07%
EcoR1 Capital, LLCdirector
3851507
7.0627%
$7.3113+28.87%
Sanofi
2477941
4.5439%
$7.3110<0.0001%
PAUL STEVEN MPresident and CEO
872351
1.5997%
$7.3110<0.0001%
GERAGHTY JAMES Adirector
76588
0.1404%
$7.3120<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Armistice Capital Llc$43.5M8.594.67M+10.29%+$4.06M0.14
BlackRock$40.94M8.084.4M+67.03%+$16.43M<0.01
Ecor1 Capital Llc$36.47M7.23.92M+1.72%+$614,823.090.26
The Vanguard Group$30.09M5.943.23M+27.75%+$6.54M<0.01
Farallon Capital$21.34M4.212.29M+77.4%+$9.31M0.15
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.